<?xml version='1.0' encoding='utf-8'?>
<document id="19354254"><sentence text="Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists." /><sentence text="3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one (17) is a high affinity, brain-penetrant, hydroisoindoline-based neurokinin-1 (NK(1)) receptor antagonist with a long central duration of action in preclinical species and a minimal drug-drug interaction profile"><entity charOffset="0-134" id="DDI-PubMed.19354254.s2.e0" text="3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one" /></sentence><sentence text=" Positron emission tomography (PET) studies in rhesus showed that this compound provides 90% NK(1) receptor blockade in rhesus brain at a plasma level of 67 nM, which is about 10-fold more potent than aprepitant, an NK(1) antagonist marketed for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV and PONV)"><entity charOffset="201-211" id="DDI-PubMed.19354254.s3.e0" text="aprepitant" /></sentence><sentence text=" The synthesis of this enantiomerically pure compound containing five stereocenters includes a Diels-Alder condensation, one chiral separation of the cyclohexanol intermediate, an ether formation using a trichloroacetimidate intermediate, and bis-alkylation to form the cyclic amine"><entity charOffset="150-162" id="DDI-PubMed.19354254.s4.e0" text="cyclohexanol" /><entity charOffset="180-185" id="DDI-PubMed.19354254.s4.e1" text="ether" /><entity charOffset="204-224" id="DDI-PubMed.19354254.s4.e2" text="trichloroacetimidate" /><entity charOffset="270-282" id="DDI-PubMed.19354254.s4.e3" text="cyclic amine" /><pair ddi="false" e1="DDI-PubMed.19354254.s4.e0" e2="DDI-PubMed.19354254.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19354254.s4.e0" e2="DDI-PubMed.19354254.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19354254.s4.e0" e2="DDI-PubMed.19354254.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19354254.s4.e0" e2="DDI-PubMed.19354254.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19354254.s4.e1" e2="DDI-PubMed.19354254.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19354254.s4.e1" e2="DDI-PubMed.19354254.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19354254.s4.e1" e2="DDI-PubMed.19354254.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19354254.s4.e2" e2="DDI-PubMed.19354254.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19354254.s4.e2" e2="DDI-PubMed.19354254.s4.e3" /></sentence><sentence text="" /></document>